Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

dated January 09, 2024

Commission File Number 0-51504

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 09, 2024

	GENETIC TECHNOLOGIES LIMITED

	By:	/s/ Tony Di Pietro
	Name:	Tony Di Pietro
	Title:	Company Secretary

EXHIBIT INDEX

Exhibit		Description of Exhibit

99.1		Resignation of Chief Financial Officer & Company Secretary

Exhibit 99.1

Resignation of Chief Financial Officer & Company Secretary

Melbourne, Australia, 8 January 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease advises that Mr Tony Di Pietro has provided his notice of resignation as Chief Financial Officer (CFO) and Company Secretary of the Company.

The Company has commenced a search for a new CFO and Company Secretary with requisite dual ASX and Nasdaq listed company expertise. Mr Di Pietro will remain in the role of CFO and Company Secretary until a replacement commences with GTG or the end of March 2024, whichever date is the earliest.

Simon Morriss, CEO of GTG commented on behalf of the GTG team, “Tony has made a significant contribution to the organisation since joining us in 2022 and we wish him the very best in his next endeavours.

2024 is shaping up to be an exciting time for GTG as we focus on driving sales growth with the recent release of our comprehensive breast and ovarian cancer test in the United States and our planned Pharmacy launch in the UK. We will aim to seek experience in investor relations and sales growth in these target markets.”

-END-

Authorised for release by the board of directors

Enquiries

Investor Relations

Adrian Mulcahy

Automic Markets

M: +61 438 630 411

E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com